Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Hemangiosarcoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Desmoid Tumors 1Carcinoma, Intraductal, Noninfiltrating 1

Interventions

pembrolizumab 46Paclitaxel 42Carboplatin 34Bevacizumab 18Specimen Handling 17Letrozole 16lenvatinib 13Magnetic Resonance Spectroscopy 12dostarlimab 11Cisplatin 11Biopsy 11olaparib 10Taxes 10Fulvestrant 9Doxorubicin 9abemaciclib 8Megestrol Acetate 8Docetaxel 8durvalumab 7atezolizumab 7Nivolumab 7Gemcitabine 7Blood Specimen Collection 7palbociclib 6Oxaliplatin 6Observation 6Fluorouracil 6niraparib 5Tirzepatide 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × 4-hydroxy-N-desmethyltamoxifen × 1 year × Clear all
NCT01273168 2025-12-23

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
40 enrolled
BreastGynecologicSarcoma

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡